28 March 2018

Novo Nordisk Foundation Ascending Investigator

David Gloriam has received DKK 10 million (€ ~1,3 M) Hallas-Møller Ascending Investigator grant from the Novo Nordisk Foundation (an ERC Consolidator-like Danish grant) for the project: GPCR Biased Signalling: Illuminating the Pathways to Function and DiseaseThe project aims to find out how just one cell-surface receptor can elicit vastly different biological, therapeutic or adverse effects when activated by natural, medicinal or abused substances. The Gloriam group will develop a new database resource to consolidate this new research field and conduct molecular modelling to select receptor targets and identify molecular mechanisms and substances.

NNF logo